EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

Journal:

Journal of Clinical Oncology

Published:

2026-06-02

DOI:

10.1200/jco-26-01072

Affiliations:

20

Authors:

22

Go to article

Institutions	Authors	Share
Ono Pharmaceutical Co., Ltd., Japan	3.000000	0.14
National Cancer Center Hospital East, Japan	2.000000	0.09
Dongsan Medical Center, KMU, South Korea	1.000000	0.05
Kyungpook National University (KNU), South Korea	1.000000	0.05
Osaka International Cancer Institute, Japan	1.000000	0.05
Gunma Prefectural Cancer Center, Japan	1.000000	0.05
CHA Bundang Medical Center, South Korea	1.000000	0.05
Seoul National University Bundang Hospital (SNUBH), South Korea	1.000000	0.05
Saitama Cancer Center, Japan	1.000000	0.05
Aichi Cancer Center, Japan	1.000000	0.05
Seoul St. Mary's Hospital, South Korea	1.000000	0.05
Korea University Guro Hospital, South Korea	1.000000	0.05
Yonsei Cancer Hospital, South Korea	1.000000	0.05
Gachon University Gil Medical Center, South Korea	1.000000	0.05
Asan Medical Center (AMC), South Korea	1.000000	0.05
National Cancer Center (NCC), South Korea	1.000000	0.05
Kanagawa Cancer Center, Japan	1.000000	0.05
China Medical University Hospital (CMUH), Taiwan	1.000000	0.05
Sungkyunkwan University (SKKU), South Korea	1.000000	0.05